Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3β activity in human breast cancer cells

Molecular Cancer Therapeutics

Volumn 6, Issue 1, 2007, Pages 362-369

  Soto Cerrato, Vanessa ^a   Viñals, Francesc ^a   Lambert, James R ^b   Kelly, Julie A ^b   Pérez Tomás, Ricardo ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DEATH RECEPTOR 4; DEATH RECEPTOR 5; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH FACTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUG ACTIVATED GENE 1; PRODIGIOSIN; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL ADHESION; CELL CYCLE; CELL STRAIN MCF 7; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA DAMAGE; DNA MICROARRAY; DRUG STRUCTURE; ENZYME ACTIVITY; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; STRUCTURE ANALYSIS; TRANSCRIPTION REGULATION; UNINDEXED SEQUENCE; UPREGULATION;

ANTI-BACTERIAL AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CYTOKINES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PRODIGIOSIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846846260     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0266     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagvi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001;6:133-46.
3. Perez-Tomas R, Montaner B, Llagostera E, Soto-Cerrato V. The prodigiosins, proapoptotic drugs with anticancer properties. Biochem Pharmacol 2003;66:1447-52.
4. Montaner B, Navarro S, Pique M, et al. Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines. Br J Pharmacol 2000;131:585-93.
5. Zang J, Shen Y, Liu J, Wei D. Antimetastatic effect of prodigiosin through inhibition of tumor invasion. Biochem Pharmacol 2005;69: 407-14.
6. Campas C, Dalmau M, Montaner B, et al. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia. Leukemia 2003; 17:746-50.
7. Diaz-Ruiz C, Montaner B, Perez-Tomas R. Prodigiosin induces cell death and morphological changes indicative of apoptosis in gastric cancer cell line HGT-1. Histol Histopathol 2001;16:415-21.
8. Montaner B, Perez-Tomas R. Prodigiosin-induced apoptosis in human colon cancer cells. Life Sci 2001;68:2025-36.
9. Soto-Cerrato V, Llagostera E, Montaner B, Perez-Tomas R. Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. Biochem Pharmacol 2004;68:1345-52.
10. Llagostera E, Soto-Cerrato V, Joshi R, Montaner B, Gimenez-Bonafe P, Perez-Tomas R. High cytotoxic sensitivity of the human small cell lung doxorubicin-resistant carcinoma (GLC4/ADR) cell line to prodigiosin through apoptosis activation. Anticancer Drugs 2005;16:393-9.
11. - symport. Biochem J 1998;334:731-41.
12. - symporter) inhibit the acidification of lysosomes and induce cell cycle blockage in colon cancer cells. Life Sci 2005;78:121-7.
13. Perez-Tomas R, Montaner B. Effects of the proapoptotic drug prodigiosin on cell cycle-related proteins in Jurkat T cells. Histol Histopathol 2003;18:379-85.
14. Melvin MS, Wooton KE, Rich CC, Saluta GR, et al. Copper-nuclease efficiency correlates with cytotoxicity for the 4-methoxypyrrolic natural products. J Inorg Biochem 2001;87:129-35.
15. Montaner B, Castillo-Avila W, Martinell M, et al. DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin. Toxicol Sci 2005;85:870-9.
16. Liu T, Bauskin AR, Zaunders J, et al. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 2003;63:5034-40.
17. Tan M, Wang Y, Guan K, Sun Y. PTGF-β, a type β transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signalling pathway. Proc Natl Acad Sci U S A 2000;97:109-14.
18. Li PX, Wong J, Ayed A, et al. Placental transforming growth factor-β is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 2000; 275:20127-35.
19. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001; 59: 901-8.
20. Monks A, Harris E, Hose C, Connelly J, Sausville EA. Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. Mol Pharmacol 2003;63:766-72.
21. Newman D, Sakaue M, Koo JS, et al. Differential regulation of nonsteroidal anti-inflammatory drug-activated gene in normal human tracheobronchial epithelial and lung carcinoma cells by retinoids. Mol Pharmacol 2003;63:557-64.
22. Wilson LC, Baek SJ, Call A, Eling TE. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Int J Cancer 2003;105: 747-53.
23. Baek SJ, Wilson LC, Eling TE. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002;23:425-34.
24. Lambert JR, Kelly JA, Shim M, et al. Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J Cell Physiol 2006;208:566-74.
25. Bottone FG, Jr., Baek SJ, Nixon JB, Eling TE. Diallyl disulfide (DADS) induces the antitumorigenic NSAID-activated gene (NAG-1) by a p53-dependent mechanism in human colorectal HCT 116 cells. J Nutr 2002; 132:773-8.
26. Lee SH, Kim JS, Yamaguchi K, Eling TE, Baek SJ. Indole-3-carbinol and 3,3′-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem Biophys Res Commun 2005;328:63-9.
27. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 2005;67:356-64.
28. Chintharlapalli S, Papineni S, Baek SJ, Liu S, Safe S. 1,1-Bis(3′-indolyl)-l-(p-substituted phenyl) methanes are peroxisome proliferator-activated receptor γ agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. Mol Pharmacol 2005;68:1782-92.
29. Shim M, Eling TE. Protein kinase C-dependent regulation of NAG-1/ placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells. J Biol Chem 2005;280:18636-42.
30. Yamaguchi K, Lee SH, Eling TE, Baek SJ. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3β pathway. J Biol Chem 2004;279:49617-23.
31. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
32. Jang TJ, Kang HJ, Kim JR, Yang CH. Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis. Carcinogenesis 2004;25: 1853-8.
33. Blagosklonny MV. P53: an ubiquitous target of anticancer drugs. Int J Cancer 2002;98:161-6.
34. Royds JA, Lacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ 2006;13:1017-26.
35. Grossmann J. Molecular mechanisms of "detachment-induced apoptosis-anoikis." Apoptosis 2002;7:247-60.
36. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-95.
37. Fujiwara Y, Kawada K, Takano D, Tanimura S, Ozaki K, Kohno M. Inhibition of the P13 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner. Biochem Biophys Res Commun 2006;340:560-6.
38. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 1998;273:19929-32.
39. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277:818-21.